Cowen reiterated their buy rating on shares of Avrobio (NASDAQ:AVRO) in a research note released on Tuesday morning, AnalystRatings.com reports.
A number of other research analysts have also commented on the stock. Zacks Investment Research lowered shares of Avrobio from a hold rating to a sell rating in a research report on Tuesday, February 12th. HC Wainwright set a $40.00 price objective on shares of Avrobio and gave the company a buy rating in a research report on Monday, April 22nd. Leerink Swann cut their price objective on shares of Avrobio from $27.00 to $19.00 and set a market perform rating for the company in a research report on Thursday, January 17th. Finally, Janney Montgomery Scott initiated coverage on shares of Avrobio in a research report on Friday, April 5th. They set a buy rating and a $24.42 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Avrobio presently has an average rating of Buy and a consensus price target of $31.06.
AVRO stock opened at $17.89 on Tuesday. Avrobio has a 52-week low of $11.85 and a 52-week high of $53.70. The stock has a market cap of $431.99 million and a price-to-earnings ratio of -4.94.
Avrobio (NASDAQ:AVRO) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.01). On average, equities research analysts predict that Avrobio will post -2.85 EPS for the current fiscal year.
In related news, insider Geoffrey Mackay sold 14,000 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $27.25, for a total value of $381,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher Paige sold 10,000 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $25.72, for a total transaction of $257,200.00. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can acquired a new position in Avrobio in the fourth quarter worth about $34,000. Legal & General Group Plc acquired a new position in Avrobio in the third quarter worth about $48,000. BNP Paribas Arbitrage SA acquired a new position in Avrobio in the first quarter worth about $59,000. New York State Common Retirement Fund acquired a new position in Avrobio in the fourth quarter worth about $113,000. Finally, American International Group Inc. raised its position in Avrobio by 102.2% in the first quarter. American International Group Inc. now owns 8,111 shares of the company’s stock worth $179,000 after purchasing an additional 4,100 shares in the last quarter. 73.82% of the stock is owned by hedge funds and other institutional investors.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More: Marijuana Stocks
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.